Cargando…
Phase 0 Clinical Trial Strategies for the Neurosurgical Oncologist
In an era of escalating drug discovery costs, shifting priorities within the pharmaceutical industry, and longstanding challenges in central nervous system drug delivery, surgical trials offer an avenue to identify promising agents with demonstrable tumor penetration and molecular effects. The rise...
Autor principal: | Sanai, Nader |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855937/ https://www.ncbi.nlm.nih.gov/pubmed/31245813 http://dx.doi.org/10.1093/neuros/nyz218 |
Ejemplares similares
-
The Value of Glioma Extent of Resection in the Modern Neurosurgical Era
por: Hardesty, Douglas A., et al.
Publicado: (2012) -
Phase 0 - Microdosing strategy in clinical trials
por: Rani, P. Usha, et al.
Publicado: (2008) -
Toward Quantitative Neurosurgical Guidance With High-Resolution Microscopy of 5-Aminolevulinic Acid-Induced Protoporphyrin IX
por: Wei, Linpeng, et al.
Publicado: (2019) -
A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma
por: Mehta, Shwetal, et al.
Publicado: (2022) -
The brain and computer: The neurosurgical interface
por: Pouratian, Nader
Publicado: (2011)